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Abstract
Background: Cardiovascular disease frequently causes morbidity and mortality in mucopolysaccharidoses (MPS);
however, cardiovascular anatomy and dysfunction in MPS IVA (Morquio A disease) is not well described.
Consequently, the study aimed to compare carotid artery structure and elasticity of MPS IVA patients with other
MPS patients and healthy control subjects, and quantitate frequency of MPS IVA cardiac structural and functional
abnormalities.
Methods: Prospective, multi-center echocardiogram and carotid ultrasound evaluations of 12 Morquio A patients
were compared with other MPS and healthy control subjects. Average differences between groups were adjusted
for age, sex, and height with robust variance estimation for confidence intervals and P-values.
Results: Morquio A patients demonstrated significantly higher (P < 0.001) adjusted carotid intima-media thickness
(cIMT), mean (SD) of 0.56 mm (0.03) compared to control subjects, 0.44 mm (0.04). The Morquio A cohort had
significantly greater adjusted carotid elasticity (carotid cross-sectional compliance + 43%, P < 0.001; carotid
incremental elastic modulus − 33%, P = 0.003) than control subjects and other MPS patients. Aortic root dilatation
was noted in 56% of the Morquio A cohort, which also had highly prevalent mitral (73%) and aortic (82%) valve
thickening, though hemodynamically significant valve dysfunction was less frequent (9%).
Conclusions: Increased carotid elasticity in Morquio A patients is an unexpected contrast to the reduced elasticity
observed in other MPS. These Morquio A cIMT findings corroborate MPS IVA arterial post-mortem reports and are
consistent with cIMT of other MPS. Aortic root dilatation in Morquio A indicates arterial elastin dysfunction, but their
carotid hyperelasticity indicates other vascular intima/media components, such as proteoglycans, may also influence
artery function. Studying MPS I and IVA model systems may uniquely illuminate the function of glycosaminoglycan-
bearing proteoglycans in arterial health.
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Background
Mucopolysaccharidosis IVA (MPS IVA, Morquio A dis-
ease, MIM#253000) is an autosomal recessive lysosomal
storage disorder caused by a deficiency of N-
acetylgalactosamine-6-sulfate sulfatase (GALNS). This
deficiency results in excessive systemic storage of the
glycosaminoglycans (GAGs) keratan sulfate (KS) and
chondroitin 6-sulfate (C6S) in tissues and organs [1].
Morquio A patients have coarse facial features, hearing
and vision loss, systemic skeletal dysplasia, dispropor-
tionate short-trunked short stature, joint abnormalities,
hepatomegaly, pulmonary compromise, and valvular
heart disease [2]. Though the focus is often on skeletal
deformities, cardiac anomalies have been reported as the
first sign of Morquio A as early as 3.6 months of age [3].
Cardiac anomalies observed in Morquio A include mitral
and/or aortic insufficiency, aortic stenosis, tricuspid re-
gurgitation, thickened interventricular septum, and
hypertrophic cardiomyopathy [3–6]. Echocardiography
indicates that cardiac lesions worsen in patients [3]. An
observational study that included 54 Morquio A patients
showed enlarged aortic roots, thickened left ventricles,
smaller end-diastolic dimensions of the heart, reduced
stroke volumes and impaired diastolic filling patterns
[7]. Effect of enzyme replacement therapy (ERT)
seemed negligible after a median follow up of 2.6–3.0
years [5, 7]. In addition, histopathology in a 20-year-
old patient revealed foam cells and macrophages in
aorta, aortic, mitral and tricuspid valves [8]. Cells in
the aortic intima and media were vacuolated with
GAGs, and elastin fibers were attenuated and frag-
mented. The intima was thickened by GAG accumu-
lation, atherosclerotic plaques were found, and the
aortic valve was hypertrophic [8].
Studies show carotid intima-media thickness (cIMT)
could be a marker of atherosclerosis and cardiovascular
risk in patients [9]. cIMT and carotid stiffness have been
consistently increased in MPS patients when compared
to age-matched controls [10, 11]. To date, no study ex-
plores cIMT in Morquio A. This study aimed to com-
pare cIMT and carotid stiffness of Morquio A patients
with other MPS patients and healthy controls.
Results
Morquio A carotid intima media-thickness
Details regarding the control and non-Morquio MPS co-
horts have been published [11, 12]. The Morquio A co-
hort (n = 12) was 58% male and 42% female (Table 1).
Patient 2 had a follow-up study visit with carotid ultra-
sound 16 months after initiating enzyme replacement.
Data from this subsequent visit are included in reporting
and statistical analysis, resulting in 13 data points
(Table 2). Although the age at visit is slightly older
(mean ± SD), (14.0 ± 10 years) due to the inclusion of
four adults, mean height of the Morquio A cohort
(108 ± 21.89 cm) was much less than the control (155 ±
18.30 cm) and non-Morquio MPS (132 ± 16.55 cm) co-
horts. The mean Morquio A cohort cIMT was 0.56 ±
0.03 mm, while the non-Morquio MPS cohort cIMT was
0.56 ± 0.06 mm, and the control cohort cIMT was 0.44 ±
0.04 mm. The mean Morquio A cIMT was 0.12mm
greater than the mean control cohort cIMT, an increase
of 25% (See Table 3 for detailed comparisons).
Comparison of mean carotid measures in all cohorts
were adjusted for sex, age, and height, known covariates
of cIMT and carotid stiffness (Table 3). The covariate-
adjusted mean cIMT of the Morquio A patients was sig-
nificantly greater than that of the control cohort (P <
0.001) and comparable to the non-Morquio MPS patient
cohort (P = 0.866).
Carotid artery compliance and distensibility assessment
In contrast to the non-Morquio MPS cohort, which had
significantly increased carotid stiffness compared to con-
trols, the Morquio A cohort demonstrated significantly
increased carotid elasticity compared to controls. Fol-
lowing adjustment for age, sex, and height, the Morquio
A cohort had significantly higher cCSC1 (+ 0.07 mm2 ·
mm Hg− 1; 95% confidence interval [+ 0.03 to + 0.11]
mm2 · mm Hg− 1; P = 0.001) and lower cIEM (− 294
mmHg; [− 503 to − 85.7] mm Hg; P = 0.006) than the
control patient cohort. This reflects a 43% increase [+
15% to 75%] in cross-sectional compliance, and a 33%
[− 49% to − 13%] reduction in incremental elastic modu-
lus, of the Morquio A patients when compared to the
control cohort. Carotid cross-sectional distensibility did
not differ significantly between Morquio A and control
cohorts (− 7.5%; [− 30% to + 12%]; P = 0.52).
The Morquio A cohort also had significantly higher
cCSC (+ 0.09 mm2 · mm Hg− 1; [+ 0.05 to + 0.14] mm2
· mm Hg− 1; P < 0.001) and lower cIEM (− 681 mmHg;
[− 984 to − 379] mm Hg; P < 0.001) than the non-
Morquio MPS cohort, indicating increased Morquio A
carotid elasticity compared to MPS patients who did
not have Morquio A syndrome. The mean Morquio
A cross-sectional compliance was 64% greater, and
the incremental elastic modulus 54% reduced, com-
pared to the non-Morquio MPS patients. Overall, age
was the strongest and most consistent significant co-
variate aside from MPS diagnosis for increasing ca-
rotid stiffness, with reduced cCSD: 29% decline per
10 years, P < 0.001; cCSC1: 17% decline per 10 years,
P < 0.001; and increased cIEM: + 48% increase per 10
years, P < 0.001).
Treatment effects upon carotid measurements
No clear differences in cIMT or other measurements
were observed in the two studies obtained from
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patient 2 (first measurement pre-ERT and second
measurement 14 months post-ERT). To further exam-
ine effects of treatment upon carotid structure and
function, a comparison was made between the pa-
tients who were receiving ERT at the time of study,
and those who were not receiving ERT. There were
no significant differences in cIMT (0.00 mm, 95%
confidence interval − 0.03 to + 0.03 mm; P = 0.92),
cCSD (− 2.20%, [− 8.91% to + 4.51%]; P = 0.52), or
cCSC (− 0.03 mm2 · mm Hg− 1, [− 0.08 to + 0.02] mm2
· mm Hg− 1; P = 0.28) between the Morquio A patients
currently treated with ERT and those not treated with
ERT adjusting for sex, age, and height (Table 4).
Morquio A patients treated with ERT had signifi-
cantly increased cIEM compared to those not treated
(+ 137, [+ 2.44 to + 271.29] mm Hg; P = 0.046). For
this comparison, height was a significant co-variate
for carotid stiffness, with reduced cCSD: − 2.98% / 10
cm, P < 0.001; cCSC1: − 0.02 mm2 · mm Hg− 1/ 10 cm,
P < 0.001; and increased cIEM: + 131 mmHg / 10 cm,
P < 0.001).
Table 1 Clinical, biochemical, and molecular characteristics of patients with Morquio A disease who participated in study




GALNS mutation Height Phenotype




1 12.7 Female Caucasian Iraq 40 pmol/mg/h 2799.55 ng/mg Cre c.230 C > G / c.230 C > G −7.0 Severe
(NR 400–2000)
2 8.3 Male Caucasian Iraq 28 pmol/mg/h 1924.52 ng/mg Cre c.230 C > G / c.230 C > G −6.1 Severe
(RR 400–2000)
3 38.4 Male Caucasian US 0.06 nmol/mg/
h
1158.20 ng/mg Cre c.1353 G > T / c.1353 G > T −3.4 Attenuated
(NV 0.95)
4 6.4 Female Chinese China 0.58 nmol/17
h/ mg
2266.21 ng/mg Cre c.106_111delCTGCTC /
c.953 T > G
−6.0 Severe
(RR 42.3–441.9)
5 18.3 Male Hispanic Mexico Not Available 479.51 ng/mg Cre c.1156C > T / 32 kb del −8.11 Severe
6 3.9 Male Hispanic US Not Available 1753.43 ng/mg Cre c.901G > T / c.1520G > T −3.73 Severe
7 8.5 Female Caucasian US Deficient Not Available c.239C > T /? −6.77 Severe
8 4.6 Female Caucasian US Not Available Not Available c.239C > T /? −6.34 Severe
9 25.9 Male Hispanic US Deficient Qualitatively Elevated Not Available −6.09 Severe




11 10.4 Female Hispanic /
Caucasian
US 0.05 U Qualitatively Elevated c.776G > A / c.1520G > T −2.23 Attenuated
(RR > 0.7)
12 16.1 Male Hispanic US 0 nmol / 17 h /
mg
8.4 mg/mmol Creat c.281G > A / c.1156C > T −4.27 Severe
(RR > 92) (NR < 6.5)
Table 2 Patient characteristics
Covariate Control Other MPS Morquio A
(n = 560) (n = 33) (n = 13)
Male 301 (53.8%) 22 (67%) 8 (61%)
Female 259 (46.2%) 11 (33%) 5 (39%)
Age at visit (years) 13.14 (4.01) 12.41 (4.74) 13.98 (10.0)
SBP (mm Hg) 106 (10.42) 107 (10.79) 103 (12.8)
DBP (mm Hg) 58.00 (7.78) 55.21 (13.54) 70.6 (12.2)
Pulse Pressure (mm Hg) 48.12 (9.49) 51.97 (11.81) 31.92 (6.53)
Height (cm) 155 (18.30) 132 (16.55) 108 (21.89)
cIMT (mm) 0.44 (0.04) 0.56 (0.06) 0.56 (0.03)
cCSD (%) 32.03 (8.35) 28.16 (15.74) 25.37 (8.81)
cCSC1 (mm2 · mm Hg−1) 0.16 (0.05) 0.14 (0.08) 0.22 (0.07)
cIEM (mm Hg) 951 (379.84) 1355 (811.82) 772 (371)
Values presented are mean (sd) or n (%) where indicated. The “Other MPS”
cohort is composed of 17 MPS I, 9 MPS II, 4 MPS IIIA, and 3 MPS VI patients.
The Morquio A data includes one patient (#2), who underwent two carotid
ultrasounds 16 months apart
SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, cIMT Carotid Intima-
Media Thickness, cCSD Carotid Cross-sectional Distensibility, cCSC1 Carotid
Cross-sectional Compliance, cIEM Carotid Incremental Elastic Modulus
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Cardiac structure and function
The Morquio A cohort had high occurrence of mitral
(72%; 8 of 11, 95% confidence interval 39 to 93%) and
aortic valve (82%; 9 of 11, [48 to 97%]) thickening
(Table 5). Though abnormal valve anatomy was fre-
quent, dysfunction was not severe. Trivial mitral valve
regurgitation was noted in 18% (2 of 11), [3 to 52%] of
Morquio patients. There did not appear to be an age
predisposition for mitral valve dysfunction, as the two
individuals were 3.9 and 8.5 years of age and were noted
to have “thickened” and “mildly dysplastic” mitral valves,
respectively. Aortic valve regurgitation was present in
27% of (3 of 11), [7 to 61%] Morquio A patients. Two
patients had trivial aortic regurgitation; they were aged
8.5 and 16.1 years. One patient had combined regurgita-
tion of both mitral and aortic valves. One patient, aged
22.3 years, had more prominent aortic regurgitation that
had resulted in mild left ventricular dilatation. No pa-
tients demonstrated abnormal cardiac contractility or
function. Aortic root dilatation, defined as a measure-
ment at the level of the Sinuses of Valsava exceeding 2
standard deviations above the mean, was also frequent
in the Morquio A population (56%; 5 of 9, [23 to 85%]).
Patient brief summaries
Patient 1
Iraqi Caucasian girl, diagnosed with Morquio A at 10.6
years of age. Sequencing of GALNS showed that she was
homozygous for the pathogenic variant c.230C > G
(p.P77R). Study echocardiography and carotid ultra-
sounds were performed at 11.2 and 12.7 years of age.
Her first Morquio A-related symptom was kyphosis at 4
months of age; she suffered from frequent upper respira-
tory infections and was unable to walk by 5 years of age.
Physical examination identified coarse facial features,
corneal clouding, macrocephaly, short nose, poor denti-
tion with wide spaced teeth, and mandibular promin-
ence. Skeletal dysplasia was evident, with short stature,
short trunk, kyphosis, lordosis, pectus carinatum, lower
rib flaring, short neck with decreased rotation and
flexion, genu valgum, platyspondyly, and marked laxity
in wrists and fingers leading to difficulties with fine and
gross motor tasks. She had contractures at knees, hips
and ankles, canal stenosis, cervical cord compression,
myelopathy and cervical instability. There was progres-
sive weakness and difficulty breathing at rest. Patient
had obstructive sleep apnea. The echocardiogram
showed mild thickening of the mitral valve, no signifi-
cant stenosis, no significant ventricular hypertrophy and
normal biventricular systolic function. Patient had her
first recombinant human GALNS (rhGALNS) enzyme
infusion at 11.6 years old without any complications. At
Table 4 Comparisons between mean carotid measures of
Morquio A patients treated with Enzyme Replacement Therapy
(ERT) and those not treated with ERT
Score Covariate Difference (95% CI) P-value
cIMT ERT (vs. not) 0.00 (−0.03, 0.03) 0.916
(mm) Female (vs. Male) −0.01 (−0.05, 0.02) 0.402
Age (per 10 yr) 0.01 (− 0.01, 0.02) 0.587
Height (per 10 cm) 0.00 (−0.01, 0.00) 0.408
cCSD ERT (vs. not) −2.20 (−8.91, 4.51) 0.520
(%) Female (vs. Male) 0.14 (−8.06, 8.34) 0.973
Age (per 10 yr) 1.31 (−4.23, 6.86) 0.643
Height (per 10 cm) −2.98 (−5.38, −0.58) 0.015
cCSC1 ERT (vs. not) −0.03 (− 0.08, 0.02) 0.279
(mm2 Female (vs. Male) −0.03 (− 0.09, 0.04) 0.465
· mm Hg−1) Age (per 10 yr) 0.01 (−0.03, 0.05) 0.686
Height (per 10 cm) −0.02 (− 0.04, − 0.01) 0.005
cIEM ERT (vs. not) 136.86 (2.44, 271.29) 0.046
(mm Hg) Female (vs. Male) 14.88 (− 145.24, 175.00) 0.855
Age (per 10 yr) 34.26 (− 105.85, 174.38) 0.632
Height (per 10 cm) 130.82 (80.41, 181.23) < 0.001
Analyses are adjusted for sex, age, and height. Significant comparisons are
highlighted in bold. Height is a significant influence upon cCSD, cCSC1,
and cIEMTable 3 Ratio comparisons between mean carotid measures of
Morquio A patients, non-Morquio MPS patients (“Other MPS”),
and pediatric control groups adjusted for sex, age, and height
Vascular Measure Covariate Ratio (95% CI) P-value
Control vs. Morquio A 0.80 (0.76, 0.84) < 0.001
Other MPS vs. Morquio A 1.00 (0.95, 1.05) 0.956
cIMT (mm) Female (vs. Male) 0.98 (0.97, 1.00) 0.038
Age (per 10 yr) 1.03 (0.99, 1.06) 0.114
Height (per 10 cm) 1.00 (0.99, 1.01) 0.931
Control vs. Morquio A 1.07 (0.88, 1.30) 0.521
Other MPS vs. Morquio A 1.02 (0.80, 1.30) 0.875
cCSD (%) Female (vs. Male) 1.01 (0.97, 1.05) 0.668
Age (per 10 yr) 0.71 (0.64, 0.79) < 0.001
Height (per 10 cm) 1.04 (1.02, 1.06) < 0.001
Control vs. Morquio A 0.70 (0.57, 0.87) < 0.001
cCSC1 Other MPS vs. Morquio A 0.61 (0.47, 0.79) < 0.001
(mm2 · mm Hg−1) Female (vs. Male) 0.95 (0.90, 1.00) 0.045
Age (per 10 yr) 0.83 (0.74, 0.93) 0.001
Height (per 10 cm) 1.01 (0.98, 1.04) 0.502
Control vs. Morquio A 1.50 (1.15, 1.96) 0.003
Other MPS vs. Morquio A 2.18 (1.63, 2.92) < 0.001
cIEM (mm Hg) Female (vs. Male) 0.95 (0.90, 1.01) 0.121
Age (per 10 yr) 1.48 (1.30, 1.70) < 0.001
Height (per 10 cm) 0.99 (0.95, 1.02) 0.364
Ratios less than 1.00 indicate the first comparator is less than the second
comparator; ratios greater than 1.00 indicate the first comparator is greater
than the second comparator. Significant comparisons are highlighted in bold
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11.7 years, she underwent tracheostomy, cervical fusion
and decompression. At 12.5 years, bilateral sensorineural
hearing loss was diagnosed.
Patient 2
Iraqi Caucasian boy; he is the younger sibling of pa-
tient 1 and was diagnosed with Morquio A at 6.2
years of age with homozygosity of the c.230C > G
(p.P77R) family variant. Study echocardiography and
carotid ultrasounds were performed at 7.9 and 9.2
years of age. Physical examination identified macro-
cephaly, coarse facial features, corneal clouding, poor
dentition, gingival hypertrophy, and mandibular prom-
inence. He had skeletal dysplasia with short stature,
short and stiff neck, platyspondyly, kyphosis at the
thoracolumbar junction, anterior beaking in vertebral
bodies, oar-shaped deformity of ribs, deformed fem-
oral heads, flat acetabular roofs, bilateral coxa valga,
genu valgum, pectus carinatum, wrist deformity, pro-
gressive joint laxity, difficulty with fine and gross
motor tasks, and diminished motion of shoulders. He
had difficulty walking, a gait problem and general
weakness. At 7 years, atlantoaxial subluxation with hy-
poplastic C2 odontoid process was confirmed, with
subsequent occipital-cervical instability, myelopathy,
and decline of ambulation. Echocardiogram showed
very mild thickening of aortic and mitral valves, no
significant valvar stenosis, regurgitation or ventricular
hypertrophy. He had normal biventricular systolic function.
Pulmonary studies suggested a narrowed oropharynx,
impaired cough clearance, severe respiratory muscle weak-
ness, neuromuscular weakness, daytime hypersomnolence,
upper airway obstruction, restrictive lung disease with
shortness of breath and obstructive sleep apnea, and mul-
tiple upper respiratory infections. First rhGALNS enzyme
replacement therapy (ERT) occurred at 7.2 years without
complications. He reported increased stamina after ERT,
but subsequently developed a rash after enzyme infusions.
Patient 3
American Caucasian man of Middle Eastern ancestry.
He was diagnosed at 12 years of age. Molecular stud-
ies identified the GALNS mutations c.1353G > T /
c.1353G > T (p.R451S/R451S). Study echocardiography
and carotid ultrasound were performed at 38.4 years
of age. His skeletal dysplasia includes decreased bone
density, generalized platyspondyly, bullet-shaped verte-
bra at the thoracolumbar junction, and generalized
central canal stenosis of the cervical spine. He also
had anterior atlantoaxial instability with a hypoplastic
or absent odontoid process. Other notable medical
problems include mild corneal clouding, joint con-
tractures, and diffuse joint, muscle, and bone pain.
Multiple surgeries have included bilateral hip replace-
ment, gynecomastia reduction, gastric bypass, and
cholecystectomy. There have been no reports of hear-
ing problems, pulmonary or cardiac symptoms. At 37,
he started enzyme replacement, which has resulted in
improvement of restricted joint mobility.
Table 5 Echocardiographic and demographic parameters of the Morquio A cohort indicating high prevalence of mitral and aortic
valve pathology, as well as aortic root dilatation. Aortic root Z-scores that indicate aortic root dilatation are highlighted in bold. n.a.;
not analyzed
Patient Mitral Valve Aortic Valve LV Size /
Function
Aortic Root Z-Score
Anatomy Function Anatomy Function
1 Mildly Thickened Normal Normal Normal Normal n.a.
2 Mildly Thickened Normal Mildly Thickened Normal Normal n.a.
3 Normal Normal Normal Normal Normal + 1.11
4 Mildly Thickened Normal Mildly Thickened Normal Normal + 2.41
5 n.a. n.a. n.a. n.a. n.a. n.a.
6 Thickened Trivial Regurgitation Thickened Normal Normal + 3.28
7 Mild Dysplasia Trivial Regurgitation Thickened Trivial Regurgitation Normal + 1.97
8 Thickened Normal Thickened Normal Normal + 1.06
9 Mildly Thickened Normal Mildly Thickened Normal Normal + 4.62
10 Normal Normal Cusp Asymmetry Moderate Regurgitation Mild dilatation + 4.92
11 Minimally Thickened Normal Minimally Thickened Normal Normal + 0.43
12 Normal Normal Slightly Thickened Trivial Regurgitation Normal + 2.43
73% Thickened 18% Regurgitation 82% Abnormal 27% Regurgitation 9% LV Dilatation 56% with Dilatation
27% Normal 82% Normal 18% Normal 73% Normal 91% Normal 44% Normal
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Patient 4
Southern Chinese girl diagnosed at age 2 years
(leukocyte GALNS 0.58 nmol/17 h/mg protein; reference
range 42.3–441.96; GALNS variants c.106_
111delCTGCTC / c.953 T > G). Study assessments were
performed at 6.4 years of age. Physical examination at
assessment demonstrated disproportionate short stature,
with a height Z-score of − 6.0; mild coarse facial features,
depressed nasal bridge, pectus carinatum, kyphosis,
ulnar deviation of forearms, genu valgum, and severe
joint hyperlaxity. Spinal magnetic resonance imaging
(MRI) identified platyspondyly with cervicomedullary
and T10 spinal canal stenosis, and absence of spinal in-
stability despite incomplete ossification of the odontoid.
Her echocardiogram identified normal left ventricular
size and function with mild thickening of the mitral and
aortic valve leaflets without regurgitation or stenosis.
The aortic root absolute measurement was 18mm (Z
score + 1.20). She received rhGALNS from age 6.4 until
age 8.2 with moderate reactions (hypotension, tachycar-
dia, nausea, and emesis). ERT was discontinued at par-
ental request due to arrest of linear growth and
progression of genu valgum.
Patient 5
Hispanic male with GALNS pathogenic variants
c.1156C > T and 32 kb deletion. At the time of study as-
sessment, he was 18.3 years old and demonstrated dis-
proportionate short stature, with a height Z-score of −
8.11; coarse facial features and depressed nasal bridge,
and ulnar deviation of his forearms with wrist and ankle
hyperlaxity. He required tracheostomy due to upper air-
way obstruction and tracheomalacia. He had been re-
ceiving rhGALNS ERT beginning at age 17.3 without
any infusion-associated reactions.
Patient 6
Hispanic male diagnosed at 2.8 years of age (GALNS
c.901G > T / c.1520G > T pathogenic variants) after pre-
senting at 3 months of age with lumbar gibbus and sub-
sequently developing disproportionate short stature. At
study assessment, he was 3.87 years old and his height Z
score was − 3.73. Physical examination identified frontal
bossing, depressed nasal bridge, pectus carinatum, thora-
columbar kyphosis, global joint hyperlaxity, and genu
valgum. Spinal MRI identified platyspondyly with mod-
erate cervical canal stenosis, and hypoplastic dens with-
out craniocervical instability. Echocardiogram identified
thickening of mitral and aortic valve leaflets with trivial
mitral valve regurgitation and normal aortic valve func-
tion. His aortic root was moderately dilated with a meas-
urement of 21.6 mm (Z score + 3.28). He began receiving
rhGALNS at age 3.2 ERT without reactions. Subse-
quently, he has required acetabuloplasty and femoral/
tibial epiphyseodesis due to hip dysplasia and genu
valgum.
Patient 7
Caucasian female who presented at 18 months of age
with genu valgum and spinal kyphosis, and subsequently
diagnosed with Morquio A at age 3 (deficient leukocyte
GALNS enzyme; one pathogenic GALNS c.239C > T
variant identified). Her echocardiogram, carotid ultra-
sound, and other study assessments were performed at
age 8.5 years. Physical examination at assessment dem-
onstrated a height Z score of − 6.77, disproportionate
short stature, depressed nasal bridge, prominent pectus
carinatum, severe wrist and ankle joint hyperlaxity, and
genu valgum. Spinal MRI showed platyspondyly, cranio-
cervical stenosis without instability, thoracic kyphosis,
and lumbar hyperlordosis. Cardiac imaging identified
trivial mitral and aortic valve regurgitation, and an aortic
root measurement of 20.6 mm (Z score + 1.97). She has
required bilateral hip acetabuloplasty and femoral/tibial
epiphyseodesis. She had received investigational
rhGALNS and declined to continue enzyme therapy.
Patient 8
She is the younger sister of patient 7 and was diagnosed
at birth due to family history. She was 4.6 years old at
time of study assessment, which identified a height Z
score was − 2.17 with physical examination significant
for disproportionate short stature, depressed nasal
bridge, pectus carinatum, mild wrist / ankle joint hyper-
laxity, thoracolumbar gibbus deformity, and genu val-
gum. Spinal MRI showed platyspondyly, and mild
cervical spinal canal stenosis without instability. Echo-
cardiogram identified thickening of the mitral and aortic
valves without valve dysfunction. The aortic root mea-
sured 18 mm (Z score + 1.06). She has also undergone
bilateral hip acetabuloplasty and femoral/tibial epiphy-
seodesis. She received investigational rhGALNS as an in-
fant and declined to continue with enzyme therapy. At
most recent clinical assessment, her short stature has
worsened, and her current height Z score is − 6.34 at age
8.25 years, demonstrating a severe Morquio A phenotype
like her older sister.
Patient 9
He is a Hispanic male initially misdiagnosed as spondy-
loepiphyseal dysplasia, subsequently identified to have
Morquio A at 15 years of age after biochemical evalu-
ation discovered elevated urinary KS and deficient fibro-
blast GALNS enzymatic activity. His study
echocardiogram, carotid ultrasound, and other evalua-
tions were performed at 25.9 years of age. Study evalu-
ation was significant for disproportionate short stature
(adult height 134.4 cm; approximate height Z score −
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6.09), minimally coarse facial features, ulnar deviation of
his forearms, mild joint hyperlaxity, and minimal genu
valgum status post femoral/tibial epiphyseodesis. He had
also undergone T10 – L3 spinal fusion due to kyphosis.
Echocardiogram identified mild thickening of the mitral
valve with neither mitral nor aortic valve dysfunction.
His aortic arch could not be well-visualized due to hab-
itus. He declined rhGALNS therapy.
Patient 10
He is a Hispanic male who was diagnosed at 3 years
of age following identification of dysostosis multiplex
and subsequent demonstration of urinary keratan sul-
faturia with deficient fibroblast GALNS enzyme (7000
units; reference range > 40,000) and eventual demon-
stration of GALNS pathogenic variants (c.1156C > T /
c.924 T > G + c.930G > C). Study assessments were per-
formed at 22.26 years of age. Physical examination
identified macrocephaly (56.5 cm), short stature (adult
height 109.2 cm; Z score − 9.1), mild corneal clouding,
coarse facial features, marked wrist and ankle joint
laxity, genu valgum, brachydactyly, pectus carinatum,
and thoracolumbar kyphosis. His echocardiogram was
significant for normal mitral valve anatomy and func-
tion, but moderate aortic valve regurgitation, mild left
ventricular dilatation (Left ventricular / LV mass
index 170.1 g/m2), and aortic root dilatation (32.9
mm, Z-score + 4.95). He had undergone occipitocervi-
cal decompression and fusion, as well as bilateral hip
osteotomies prior to study assessments. He has been
treated with rhGALNS without reactions.
Patient 11
She is a Cuban/Caucasian female, first noted by parents
at 2 years of age to have lumbar kyphosis. Subsequent
spinal MRI suggested MPS, and biochemical evaluations
identified elevated urinary KS, deficient fibroblast
GALNS (0.05 units, reference range > 0.7), and eventual
molecular confirmation of GALNS pathogenic mutations
(c.776G > A / c.1520G > T). Study echocardiography,
ultrasound, and examination occurred at 10.4 years of
age. Study physical examination identified mild dispro-
portionate short stature (height Z-score − 2.23), minim-
ally coarse facial features, normal corneas, absence of
pectus carinatum, and mild joint hyperlaxity. S-shaped
curvature of the cervical-thoracic junction manifested
with cord compression at age 11 and required decom-
pression with spinal fusion. Her echocardiogram showed
minimally redundant mitral and aortic valve leaflets
without regurgitation or stenosis. Her aortic root mea-
sured 21mm (Z-score + 0.43). She has been treated with
intravenous rhGALNS without complications.
Patient 12
Hispanic male whose first notable symptom of Morquio
A was pectus carinatum at age 2 years. After developing
abnormal gait at 5 years of age, he was referred for clin-
ical genetics evaluation and formally diagnosed with
Morquio A at age 8. Urinary GAG excretion was ele-
vated; his leukocyte GALNS activity was undetectable,
and sequencing of GALNS identified c.281G > A /
c.1156C > T pathogenic variants. Study assessments were
performed at 16.1 years of age. Study physical exam
demonstrated disproportionate short stature (height Z-
score − 4.27), mild facial coarseness, pectus carinatum,
thoracolumbar gibbus, forearm ulnar deviation, and
hyperlaxity of joints. Mitral valve anatomy and function
were normal, while he demonstrated trivial aortic valve
regurgitation. Aortic root was mildly dilated, measuring
28.2 mm (Z-score + 2.23). He has been treated with
intravenous rhGALNS without reactions.
Correlation between genotype and phenotype
Patients 1 and 2 are homozygous for the mutation
p.P77R (c.230C > G) in exon 2, which is associated with
a severe phenotype due to a non-conservative change of
proline to arginine in a conserved amino acid region of
GALNS affecting its hydrophobic core [13, 14]. These
patients show mildly thickened mitral valve and/or
mildly thickened aortic valve with normal function. Pa-
tients 3 and 11 exhibit an attenuated phenotype based
on their growth charts. Despite the difference in their
age and gender, these patients have normal or minimally
thickened mitral and aortic valves with normal function
and normal aortic root Z score. Patient 3 is homozygous
for the novel mutation p.R451S (c.1353 G > T) in exon
12 that is likely to be pathogenic with an in-silico score
of 0.918 (sensitivity: 0.81; specificity: 0.94) [15]. Patient
11 has the allele c.776 G > A (p.R259Q, in exon 8), which
is located on the surface of GALNS enzyme and gives an
attenuated phenotype [13]. The other allele was c.1520
G > T (p.C507F) in exon 14 which has been classified as
“likely disease-associated” mutation and has not been
characterized in detail [16].
Patients 10 and 12 (22.3 and 16.1 years old, respect-
ively) have severe phenotype of the disease with aortic
valve pathology including cusp asymmetry or slightly
thickened aortic valves with moderate regurgitation. In
addition, both patients show a dilated aortic root. Their
genotypes share the allele c.1156C > T (p.R386C) which
is the most frequently reported GALNS mutation, lo-
cated in exon 11 and associated with severe phenotype
[14, 17, 18].
Patients 4 and 6, who were 6.4 and 3.9 years of age,
have severe phenotype with severe heart disease evi-
denced by mitral and aortic valve pathology. Both have
exon 9 mutations (p.M318R and p.G301C) known to
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impact protein folding and cause severe phenotype [13,
19–21].
Patients 7 and 8 (8.5 and 4.6 years old, respectively)
are siblings with severe phenotype with mitral and valve
pathology but with normal aortic root Z-score. They
share the mutation p.S80L which affects the active site
of GALNS enzyme [21–23]. The other allele has not
been elucidated, but the Morquio A diagnosis is secure
given patient 7’s low GALNS enzymatic activity.
Discussion
This study of twelve patients with MPS IVA, or Morquio
A disease, demonstrates a high prevalence of structural
and functional abnormalities in their carotid arteries and
left-sided cardiac valves. The small MPS IVA cohort and
the cross-sectional nature of sonographic assessments
represent limitations to this study; however, we have uti-
lized the same approach for statistical analyses with
other, similarly-sized MPS cohorts [11, 12].
Carotid intima-media thickness
Mean cIMT of Morquio A patients was 0.56 mm, com-
parable to the mean cIMT of 0.56 mm found in 33 pa-
tients with other types of MPS (17 MPS I, 9 MPS II, 4
MPS IIIA, and 3 MPS VI), and 0.12 mm (26%) thicker
than the mean cIMT of a large, healthy control cohort.
ERT did not affect cIMT measurements in the Morquio
A cohort. The mechanism of cIMT thickening in Mor-
quio A is very similar to other MPS types: a combination
of mechanical expansion caused by GAG storage, extra-
cellular matrix proliferation, and recruitment of myofi-
broblasts and activated macrophages throughout arterial
vasculature [12]. The in vivo cIMT findings corroborate
the post-mortem examination of aortic intima and
media from a 20-year old male with Morquio A disease,
which identified infiltration of foamy GAG-laden macro-
phages and abundant accumulation of C6S within the
intima-media matrix [8].
Mitral and aortic valve disease
Hypertrophy of the decedent’s mitral and aortic valves,
which contained large numbers of foam cells and inflam-
matory T-cell and macrophages has been reported [8].
Such findings correlate with the in vivo findings of our
Morquio A cohort, which demonstrated a high propor-
tion of patients with thickening of the mitral and aortic
valves, and a smaller percentage who had valvular regur-
gitation. Age did not clearly correlate with severity of
valve thickening or dysfunction. Valve thickening was
observed in young and adult patients alike, and the three
patients who did not have mitral valve thickening were
16.1, 22.3, and 38.4 years old. Young patients’ valve
thickening may reflect greater Morquio A severity. Like-
wise, absence of valve thickening in the oldest patient
reflects a more attenuated disorder. Despite this observa-
tion, we note that the 22.3-year-old who had a normal
mitral valve also had the most dysplastic and regurgitant
aortic valve. Thus, valve disease in Morquio A may also
be simultaneously discordant and progressive (this pa-
tient’s aortic regurgitation worsened with age).
Carotid hyper-elasticity
An unexpected finding of this study was markedly in-
creased carotid elasticity in Morquio A patients. The
Morquio A cohort had cCSC1 that was 43% and 64%
greater than the control and non-Morquio A MPS co-
horts, and a cIEM that was 33% and 54% reduced com-
pared to the control and non-Morquio A MPS cohorts.
This is counter to the significantly reduced carotid elas-
ticity in patients with non-Morquio A MPS previously
identified by our group [10–12]. Compliance or distensi-
bility did not differ between Morquio A patients on or
off ERT, but cIEM was higher in the ERT-treated group
after adjustment for sex, age, and height. Whether this
difference is an effect of treatment will require add-
itional, longitudinal assessments. Elastin, a highly abun-
dant protein within the arterial media, is arranged in
tightly coiled laminae and allows arteries to withstand
blood pressure oscillations throughout the cardiac cycle.
Attenuated, fragmented arterial elastin laminae have
been observed in MPS types I, VI, and VII patients and
animal models [12, 24], a result of proteolysis by cathep-
sins and matrix metalloproteinases secreted by GAG-
activated macrophages [25]. We hypothesized that re-
duced carotid elasticity in MPS I, II, IIIA, and VI pa-
tients was a consequence of the destruction in arterial
elastin. Precedence for this hypothesis comes from Mar-
fan syndrome patients, where disarrayed and fragmented
arterial elastin fibrils are a cardinal feature, giving rise to
reduced carotid compliance and distensibility and ultim-
ately life-threatening aortic root dissection [26]. Since
elastin attenuation and fragmentation was observed in
Yasuda’s Morquio A patient [8], we expected the Mor-
quio A cohort to demonstrate abnormally low carotid
elasticity compared to our other MPS cohorts.
Despite the unexpectedly increased carotid elasticity in
the Morquio A cohort, the cohort’s high prevalence of
aortic root dilatation (56%), comparable to the 69% (11
of 16) prevalence in an independently ascertained Mor-
quio A cohort [27] and a high prevalence in older Mor-
quio A patients [7] comprise evidence that pathology of
arterial elastin in Morquio A has clinical significance.
While no Morquio A patient has yet been reported to
experience aortic dissection, improved life spans of MPS
IVA patients necessitate education for families and phys-
ician providers to recognize and promptly seek medical
intervention if dissection symptoms develop. An add-
itional potential step, mirroring aortic root management
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in Marfan syndrome, would be to determine what mag-
nitude of aortic root dilatation, if any, would warrant
elective surgical correction. The existence of multiple
co-morbidities in Morquio A, notably airway access
challenges [28], redundancy and malacia of the tracheo-
bronchial tree [29], and risk of watershed spinal ische-
mia [30], result in an extremely high-risk surgery. Thus,
the authors are reluctant to recommend any aortic root
surgery until further natural history studies document
the occurrence of aortic root dissection in Morquio A.
Carotid hyper-elasticity in the context of arterial elas-
tin fragmentation in Morquio A seems incongruous, but
may uniquely illuminate the function GAG-bearing pro-
teoglycans (PGs) in arterial health. Differences in GAG
species accumulated in Morquio A (KS and C6S), com-
pared to MPS types I / II / VI (heparan and dermatan
sulfates; HS and DS, respectively), may be the key to un-
derstanding the stark differences in carotid function be-
tween Morquio A and other types of MPS. GAGs
represent 1–2% of arterial dry weight in healthy individ-
uals [31, 32]. Attached to PGs and secreted into the
extracellular matrix, they form complexes with elastin,
collagen, and other fibrillar proteins that generate visco-
elastic properties required to maintain arterial integrity
through a lifetime of cardiac cycles. Alterations in bal-
ance between KS, C6S, HS, and DS-bearing PGs may
alter arterial elastic properties independent of elastin
content. Indeed, versican, a C6S-PG, is known to accu-
mulate in early intimal thickening, large atherosclerotic
lesions, and areas of vascular injury and serves as a lig-
and for inflammatory macrophage adhesion and chemo-
kines [33]. Short of atherosclerosis, many of these
findings are observed in Morquio A patients and model
systems, making such versican and other KS/C6S-bear-
ing PGs the focal point of MPS vascular pathology inves-
tigation. Perhaps these investigations will also explain
joint hyperlaxity only observed in Morquio A patients, a
contrast to the joint stiffness and contractures in all
other MPS types. Additional studies are in progress to
better document the cardiovascular natural history in
Morquio A patients, and to compare with great detail
the alterations and downstream effects of arterial KS/
C6S storage in the Morquio A model system, versus ar-
terial HS/DS storage in MPS I model system.
Conclusions
Carotid hyper elasticity, increased thickening of left-
sided heart valves, and increased cIMT constitute most
of the structural and functional abnormalities observed
in this cohort of 12 Morquio A patients. Since cardiac
lesions worsen with time, patients should be evaluated
periodically by their cardiologist. Adding carotid ultra-
sonography with evaluation of cIMT and vessel elasticity
to the diagnostic toolbox will aid in understanding
Morquio A progression and evaluating current and
novel treatment strategies.
Methods
Study aim, design, and settings
The study aimed to compare echocardiographic findings
and carotid intima-media thickness and stiffness in indi-
viduals with Morquio A disease, other MPS types, and
unaffected controls utilizing a prospective, case-control
design. The study took place at Children’s Hospital of
Orange County, Saint Louis University, and the Univer-
sity of Minnesota.
Human subjects
Studies were conducted following informed consent /
assent (CHOC IRB#131107, SLU IRB#24454). Morquio
A was diagnosed based on reduced GALNS enzyme ac-
tivity of ≤5% the normal level in plasma, fibroblasts or
leukocytes, and/or via GALNS molecular testing demon-
strating two or more pathogenic mutations. All Morquio
A patients followed clinically at CHOC and Saint Louis
University were eligible for the study, and all enrolled;
control patients were ascertained at the University of
Minnesota. We classified disease severity by patient
height, with attenuated disease classified as ≥90th centile
height isopleth, and severe disease as <90th centile
height isopleth for Morquio A patients [34]. Patient
urine was collected after obtaining informed patient con-
sent or guardian assent. Enzyme activity in patient sam-
ples was compared to activity in urine samples from five
healthy controls to confirm Morquio A diagnosis. Chart
review was conducted for the 12 Morquio A patients,
and relevant summaries of clinical, biochemical, radio-
graphic, and molecular diagnostics evaluations are sum-
marized in Table 1.
Carotid ultrasound
Ultrasonographers with at least 7 years of experience ex-
amined patients, assisted by a senior technologist. All
exams were performed with a General Electric Logiq E9
machine (GE Healthcare, Waukesha, WI) and linear 9
mHz transducer. A standard automated blood pressure
monitor was used with pediatric cuff. Subjects were
placed supine without a pillow and with legs uncrossed.
Subjects were then asked to extend their neck and tilt
their head back and to the right to expose the left com-
mon carotid artery. Subjects were asked to close their
mouths and to not speak or swallow during the exam.
An automatic blood pressure cuff was applied to the
right upper arm. The ultrasound transducer was placed
approximately 10 mm proximal to the bifurcation of the
internal and external carotid arteries in the longitudinal
plane. The transducer was manipulated to optimize
visualization of the far wall intima-media thickness.
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Presets were adjusted to carotid mode; parameters such
as focal zone placement, gain, and time gain compensa-
tion were optimized by the examiner on a case by case
basis. The automatic blood pressure machine was en-
gaged. The technologist then took a 10-s cine series
while blood pressure was obtained. Exams were saved in
the Picture Archiving and Communication System
(PACS) and analyzed at a central facility (University of
Minnesota). Of note, Patient 2 underwent two carotid
ultrasounds at 7.0 and 8.4 years of age. Data from both
time points are reported and incorporated in statistical
analyses.
Carotid structure and function definitions
Carotid intima-media thickness (cIMT), cross-sectional
distensibility (cCSD), cross-sectional compliance
(cCSC1), and incremental elastic modulus (cIEM) [35]
were calculated utilizing Vascular Research Tools 5,
Medical Imaging Application, LLC, Coralville, IA, USA.
Although multiple technicians were involved in collec-
tion of carotid ultrasounds, this software suite automates
the quantification of the parameters and is operator-
independent, minimizing any variability between techni-
cians [35].
cCSD is defined by the percentage change in area of
the carotid lumen from diastole to systole and is defined





where sD indicates the maximum carotid lumen diam-
eter during systole, and dD is the minimum carotid
lumen diameter during diastole. A higher vessel cCSD
indicates increased elasticity / reduced stiffness; a lower
vessel cCSD corresponds to reduced elasticity / in-
creased stiffness.
cCSC1, which has a unit of mm2 / mm Hg, is defined
by the relative change in carotid lumen area from dia-
stole to systole per unit change in blood pressure and is
defined by the equation:




where SBP and DBP refer to systolic and diastolic blood
pressure, respectively. Another way to conceptualize
cCSC1 is the increase in carotid lumen area for each in-
crease in blood pressure of 1 mmHg. Similar to cCSD,
increasing cCSC1 represents increased elasticity / re-
duced stiffness (more change in carotid area for a given
change in blood pressure), and vice versa.
Finally, cIEM represents the carotid elasticity constant.
Increased cIEM indicates more difficulty to distend the
vessel and therefore reduced elasticity / increased
stiffness, and vice versa. The equation for cIEM, which







Apparatus and sample preparation
The chromatographic system consists of an HP1100 sys-
tem (Agilent Technologies, USA) and a Hypercarb col-
umn (2.0 mm i.d. 150 mm, 5 μm, Thermo Electron,
USA). An API-4000 mass spectrometer (Applied Biosys-
tems) equipped with a turbo ionspray ion source was
used. Stock solution of Galß1,4GlcNAc(6S) (500 μg/ml),
ΔDiHS-0S (100 μg/ml), ΔDiHS-NS (10 μg/ml), ΔDi-4S
(100 μg/ml), ΔDi-6S (100 μg/ml) (Seikagaku, Tokyo,
Japan), and internal standard (IS-chondrosine) (50 μg/
ml) (Glycosyn, New Zealand) were prepared in water.
Urine was centrifuged and supernatants digested over-
night with 1 mU of chondroitinase b, 1 mU heparitinase,
and 1 mU keratanase II (Seikagaku, Tokyo, Japan) in
buffer solution (1% BSA, 50 mM Tris-HCl, 5 mg/ml
Chondrosine). Recovered samples were analyzed by the
liquid chromatography-tandem mass spectrometry (LC-
MS/MS) system and normalized by creatinine concen-
tration in urine. Disaccharide GAG concentrations were
calculated by Analyst 1.5.1 software (AB SCIEX, Foster
City, CA).
Statistical analysis
Descriptive summaries were tabulated separately by dis-
ease group. These included the mean and standard devi-
ation for continuous variables and frequency for
categorical variables. One MPS IVA patient was mea-
sured at two time points, 1.35 years apart: both measure-
ments were included in analysis. Confidence intervals
for proportions were computed by inverting the score
test. Linear regression was used to evaluate differences
in mean values between groups adjusting for age, sex,
and height with robust variance estimation used for con-
fidence intervals and P-values. Regression to evaluate ra-
tios of means were evaluated similarly, but with a log-
link. Statistical analyses were performed using R v3.5.1
[36].
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